Publications
Publications
Show Results For
- All HBS Web
(482)
- Faculty Publications (237)
- February 2012
- Article
A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational
By: Prithwiraj Choudhury, James Geraghty and Tarun Khanna
We build on the emerging literature of influence-based models to study how multinational firms can navigate host governments. Our "core-periphery" framework posits that the actions that an MNC takes with actors in what we call the "periphery"—comprised of state,... View Details
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details
- September 2011
- Teaching Note
Tengion: Bringing Regenerative Medicine to Life (TN)
By: Elie Ofek and Natalie Kindred
Teaching Note for 510031. View Details
- June 2011 (Revised October 2013)
- Case
Gene Patents (A)
By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues... View Details
- April 2011
- Teaching Note
Office of Technology Transfer - Shanghai Institutes for Biological Sciences (TN)
By: Willy Shih and Sen Chai
Teaching Note for 611057. View Details
- March 2011 (Revised June 2012)
- Case
Office of Technology Transfer - Shanghai Institutes for Biological Sciences
By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland
Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,... View Details
- January 2011 (Revised March 2011)
- Case
Predictive Biosciences
By: Thomas R. Eisenmann, Jeffrey J. Bussgang and David Kiron
A small cancer diagnostics start-up is deciding whether to acquire a laboratory to make and sell its bladder cancer test or build its own manufacturing and sales team. View Details
- January 2011 (Revised January 2012)
- Supplement
The Case of the Unidentified Healthcare Companies2010 (CW)
By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- January 2011 (Revised January 2012)
- Case
The Case of the Unidentified Healthcare Companies2010
By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- December 2010
- Teaching Note
Roche's Acquisition of Genentech (TN)
By: Bo Becker and Carliss Y. Baldwin
Teaching Note for 210-040. View Details
- November 2010 (Revised July 2012)
- Teaching Note
Arcadia Biosciences: Seeds of Change (TN)
By: Arthur A. Daemmrich and Forest L. Reinhardt
Teaching Note for 709019. View Details
Keywords: Biotechnology Industry
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
- 2010
- Working Paper
Venture Capital Investment in the Clean Energy Sector
By: Shikhar Ghosh and Ramana Nanda
We examine the extent to which venture capital is adequately positioned for the rapid commercialization of clean energy technologies in the United States. While there are several startups in clean energy that are well-suited to the traditional venture capital... View Details
- June 2010 (Revised May 2017)
- Teaching Note
Sydney IVF: Stem Cell Research
By: Robert Simons and Kathryn Rosenberg
Teaching Note for 109017. View Details
Keywords: Strategy And Execution; Management Control Systems; Levers Of Control; Strategy; Risk Management; Decisions; Cooperative Ownership; Product Development; Moral Sensibility; Governing Rules, Regulations, and Reforms; Expansion; Science-Based Business; Research; Management Practices and Processes; Business Subsidiaries; Biotechnology Industry; Sydney
- June 2010
- Teaching Note
Monsanto: Helping Farmers Feed the World (TN)
By: David E. Bell and Mary Louise Shelman
Teaching Note for [510025]. View Details
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
- February 2010
- Case
Amyris Biotechnologies: Commercializing Biofuel
By: Gary P. Pisano and Alison Berkley Wagonfeld
In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details